ClinicalTrials.gg
CompletedNCT00800748Updated May 22, 2017

A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C

A Phase 4 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 35 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-22.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Feb 2006, registered Dec 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
372
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
17th of 83
372 · median 129
Started
2006
with 9 others
Phase 4
48 of 83
none open now
Registered
48th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 17th largest by enrollment, is one of 10 that started in 2006, is one of 48 in phase 4, and was the 48th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This 3-arm study assessed the safety and efficacy of combination treatment with peginterferon alfa-2a + ribavirin in participants with chronic hepatitis C. Three groups of participants were studied; 1) those with elevated alanine transaminase (ALT) levels, 2) those with normal ALT levels, and 3) those with human immunodeficiency virus (HIV) co-infection. Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) once weekly (qw) + ribavirin 1000-1200 milligrams (mg) orally (PO) daily (dependent on body weight) for 48 weeks. Those with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks, and all participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants at least 18 years of age
  • Chronic , with detectable serum hepatitis C virus (HCV) ribonucleic acid (RNA)
  • Scheduled for treatment with peginterferon alfa-2a
  • Compensated liver disease
  • Women in fertile age must be informed about obligation of using adequate during and 6 months post treatment with ribavirin (Copegus®)
  • Men with a sexual partner in fertile age must be informed about obligatory contraception preventing pregnancy during the course of treatment with ribavirin (Copegus®) as well as 6 months after treatment cessation
  • Female participants in the study must have a negative pregnancy test performed not sooner than within 2 weeks preceding the planned inclusion to the study
  • Men with a sexual partner in fertile age must produce a negative result of the partner's pregnancy test performed not sooner than within 2 weeks preceding the planned partner's inclusion to the study

Exclusion criteria

Exclusion Criteria:

  • Chronic liver disease other than chronic
  • Active hepatitis A virus or virus infection
  • Therapy with any systemic antiviral, antineoplastic or immunomodulatory treatment less than or equal to (\<=) 6 months prior to first dose of study drug
  • \<120 grams per liter (g/L) in female participants or \<130 g/L in male participants (the result must not be older than 2 weeks prior to inclusion to the study)
  • count \<90 x 10\^9/liter (the result must not be older than 2 weeks prior to inclusion to the study
  • Neutrofil count \<1.5 x 10\^9/liter (the result must not be older than 2 weeks prior to inclusion to the study)
  • Participants with increased risk of anaemia, or participants at risk of serious health problems resulting from anaemia or decrease of hemoglobin (e.g., participants with serious cardiovascular or cerebrovascular disease)
  • History or presence of a serious mental disease, especially depression, which, in the investigator's opinion, does not allow administration of peginterferon alfa-2a (Pegasys®)
  • History or presence of a disease consequent to immunodeficiency (e.g., inflammatory diseases of intestine, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, rheumatoid arthritis)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
372 participants (actual)

Study arms

  • Experimental
    Group A

    Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

  • Experimental
    Group B

    Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

  • Experimental
    Group C

    Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

Interventions

  • Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.

    Also known as: Pegasys

  • Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.

    Also known as: Copegus

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virological Response

    Sustained virological response is defined as having no hepatitis C (HCV) virus detectable in the blood 24 weeks after end of treatment.

    Time frame: Up to 72 weeks

Secondary outcomes

  1. Percentage of Participants With End-of-Treatment Virological Response

    End-of-treatment virological response is defined as having no HCV virus detectable in the blood immediately after end of treatment.

    Time frame: Up to 48 weeks

  2. Percentage of Participants With Early-Treatment Virological Response

    Early-treatment virological response is defined as having no HCV virus detectable in the blood or a 2-log (100-fold) decrease in HCV virus concentration in the blood after 12 weeks of study treatment.

    Time frame: Up to 12 weeks

  3. Percentage of Participants With Adverse Events

    An adverse event is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsen during the study are reported as adverse events.

    Time frame: Up to 72 weeks

07

Study locations

35 sites
  • Beroun, Czechia
  • Brno, 62500, Czechia
  • Ceska Lipa, Czechia
  • Ceské Budejovice, 370 87, Czechia
  • Chomutov, Czechia
  • Decin, 0, Czechia
  • Havirov, Czechia
  • Havlickuv Brod, Czechia
  • Hradec Kralove, 500 12, Czechia
  • Hradec Kralove, Czechia
  • Jablonec/nisou, 466 60, Czechia
  • Jihlava, Czechia
  • Karlovy Vary, Czechia
  • Kolin, Czechia
  • Liberec, Czechia
  • Melnik, Czechia
  • Most, Czechia
  • Olomouc, Czechia
  • Opava, Czechia
  • Ostrava, 708 52, Czechia
  • Pardubice, Czechia
  • Praha 2, 128 08, Czechia
  • Praha, 00000, Czechia
  • Praha, 140 00, Czechia
  • Praha, 180 01, Czechia
  • Praha, Czechia
  • Prostejov, Czechia
  • Usti Nad Labem, Czechia
  • Banska Bystrica, 957 17, Slovakia
  • Bratislava, 833 05, Slovakia
  • Bratislava, 851 07, Slovakia
  • Kosice, 040 01, Slovakia
  • Kosice, 04001, Slovakia
  • Martin, 036 59, Slovakia
  • Trencin, 911 07, Slovakia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2006 to primary completion in Jan 2009, 35 months.

Of 24 phase 4 interventional studies under Hepatitis C, Chronic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 48. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2008
First posted
Dec 2, 2008
StartActual
Feb 1, 2006
Primary completionActual
Jan 9, 2009
CompletionActual
Jan 9, 2009
Last update
May 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00800748
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 2, 2008
Start date
Feb 1, 2006
Primary completion
Jan 9, 2009
Completion
Jan 9, 2009
Last update
May 22, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion